Last reviewed · How we verify
Pazopanib as add-on to vinflunine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Pazopanib as add-on to vinflunine (Pazopanib as add-on to vinflunine) — Prof. Dr. Thomas Otto.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pazopanib as add-on to vinflunine TARGET | Pazopanib as add-on to vinflunine | Prof. Dr. Thomas Otto | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pazopanib as add-on to vinflunine CI watch — RSS
- Pazopanib as add-on to vinflunine CI watch — Atom
- Pazopanib as add-on to vinflunine CI watch — JSON
- Pazopanib as add-on to vinflunine alone — RSS
Cite this brief
Drug Landscape (2026). Pazopanib as add-on to vinflunine — Competitive Intelligence Brief. https://druglandscape.com/ci/pazopanib-as-add-on-to-vinflunine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab